NEW YORK ( TheStreet) -- Gilead Sciences (GILD) has been a serious laggard among Jim Cramer's "Four Horsemen" of biotech stocks, as Biogen Idec (BIIB) , Celgene (CELG) and Regeneron (REGN) have all continued higher.
"This is a big call," Cramer, the co-manager of the Action Alerts PLUS portfolio, said on CNBC's "Cramer's Stop Trading" segment. According to the research note, Gilead will generate $30 billion in cash over the next two years and $80 billion in cash over the next five years.
Investors shouldn't be concerned with the pricing of AbbVie's (ABBV) hepatitis C treatment either, the analysts say. It's time for Gilead Sciences to catch up to its peers and trade higher. It may be "done muddling through," Cramer concluded.
-- Written by Bret Kenwell
TheStreet Ratings team rates GILEAD SCIENCES INC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:
"We rate GILEAD SCIENCES INC (GILD) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results."
You can view the full analysis from the report here: GILD Ratings Report